NCT05940428View on ClinicalTrials.gov

A Study of ASKG712 in Patients With Diabetic Macular Edema

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

October 23, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Diabetic Macular Edema
Interventions
BIOLOGICAL

ASKG712

ASKG712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.

Trial Locations (1)

Unknown

Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing

Sponsors
All Listed Sponsors
collaborator

Suzhou Aosaikang Biopharmaceutical Co., Ltd.

UNKNOWN

lead

AskGene Pharma, Inc.

INDUSTRY